The grades of eight biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Top 5 Defensive Companies To Own In Right Now: Compucon Computer Applications SA (COMP)
Compucon Computer Applications SA is a Greek company engaged mainly in the information technology sector. The Company's activities include the manufacture and trade of electronics and software for the embroidery, telematics, laser, Web solutions and medical fields. In the embroidery field it offers album presentation or embroidery designs, lettering with a variety of fonts, frames and specialized features, and realistic three-dimensional views of embroidery designs. The Company also produces laser cutting and engraving devices for the embroidery sector. The range of telematics applications includes automotive positioning systems, fleet management and navigation systems. Its Web solutions offering includes the SiteCosmos, which is an integrated tool for on-line content management and Website design for small and medium enterprises, while the medical applications target the management of patient-oriented information, diet schedules, word processing, prescriptions and other services. Advisors' Opinion:- [By Victor Reklaitis]
The Nasdaq Composite (COMP) �rose 8.71 points, or 0.2%,to end at 4,368.04, its highest finish since April 2000. The tech-heavy index saw a 1.3% weekly rise.
Hot Up And Coming Companies For 2014: Henry Schein Inc. (HSIC)
Henry Schein, Inc. distributes healthcare products and services primarily to office-based healthcare practitioners. It operates in two segments, Healthcare Distribution and Technology. The Healthcare Distribution segment offers consumable dental products, dental laboratory products, and small equipment, including X-ray products, infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, and abrasives; and large dental equipment comprising dental chairs, delivery units and lights, X-ray equipment, equipment repair, and high-tech equipment. It also provides medical products, including branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins; and animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment. The Technology segment offers softwar e and related products, and value-added products that primarily include practice management software systems for dental and medical practitioners, and animal health clinics. Its services also consist of financial services and continuing education services for practitioners. Henry Schein, Inc. primarily serves dental practitioners and laboratories, physician practices, and animal health clinics, as well as government and other institutions. It operates in the United States, Australia, Austria, Belgium, Canada, China, the Czech Republic, France, Germany, Hong Kong, Ireland, Israel, Italy, Luxembourg, the Netherlands, New Zealand, Portugal, Slovakia, Spain, Switzerland, and the United Kingdom. The company was founded in 1932 and is headquartered in Melville, New York.
Advisors' Opinion:- [By Charles Mizrahi]
Several stocks in our portfolio will benefit from this trend: Drugstore chain Walgreens (WAG), healthcare products distributor Henry Schein (HSIC), and pharmaceutical maker AstraZeneca (AZN)
- [By John Bonnanzio]
The fund�� top holdings are Telsa, Henry Schein (HSIC), United Rentals (URI), Gartner (IT) and Kansas City Southern (KSU).
The fund also has some exposure to pricey biotech. Even so, this is hardly a shoot-the-lights-out growth fund as volatility is below all his mid-cap peers. To that end, this trade actually tempers risk while increasing growth exposure.
Hot Up And Coming Companies For 2014: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Sarepta Therapeutics (NASDAQ: SRPT) and STAAR Surgical Company (NASDAQ: STAA). In trading on Monday, basic materials shares were relative laggards, down on the day by about 0.45 percent. - [By Keith Speights]
Sometimes, even the hint of an unfavorable regulatory decision can impact a biotech stock. Sarepta Therapeutics (NASDAQ: SRPT ) shares lost more than 25% of their value in April. There wasn't an outright adverse FDA decision in this case. Instead, the FDA requested additional information related to a potential accelerated approval for Duchenne muscular dystrophy drug eteplirsen.
- [By Sean Williams]
What: Shares of Sarepta Therapeutics (NASDAQ: SRPT ) , a biopharmaceutical company focused on RNA-based therapies, fell as much as 16% after updating its status in an attempt to gain an accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen.
- [By Roberto Pedone]
One name that's starting to trend within range of triggering a big breakout trade is Sarepta Therapeutics (SRPT), which discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen. This stock has been uptrending strong so far in 2013, with shares up 45%.
If you take a look at the chart for Sarepta Therapeutics, you'll notice that this stock has been uptrending strong over the last month, with shares moving higher from its low of $29.71 to its intraday high of $38.16 a share. During that uptrend, shares of SRPT have been consistently making higher lows and higher highs, which is bullish technical price action. Shares of SRPT have now started to spike back above its 50-day moving average of $37.50, and that move is quickly pushing SRPT within range of triggering a big breakout trade.
Traders should now look for long-biased trades in SRPT if it manages to break out above its 50-day at $37.50 a share and then once it clears some key near-term overhead resistance at $39.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.65 million shares. If that breakout hits soon, then SRPT will set up to re-test or possibly take out its next major overhead resistance levels at $46 to $47 a share.
Traders can look to buy SRPT off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $35.31 to $35 a share. One can also buy SRPT off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Up And Coming Companies For 2014: Western Copper and Gold Corp (WRN)
Western Copper and Gold Corporation (Western), formerly Western Copper Corporation, is an exploration-stage company. The Company is engaged in the development of the Casino mineral property located in Yukon, Canada. The Casino property contains gold, copper, and molybdenum. The Casino Project is an open-pit mine and concentrator complex located in the Yukon Territory of Canada. The Casino property consists of 705 full and partial active quartz mineral claims. The total area covered is 13,124 hectares. CRS Copper Resources Corp. (CRS), a 100% owned subsidiary of the Company, is the registered owner of all claims. On October 17, 2011, the Company completed a plan of arrangement (the Arrangement) involving the Company and two of its subsidiaries Copper North Mining Corp. (Copper North), and NorthIsle Copper and Gold Inc. (NorthIsle). Pursuant to the Arrangement, it transferred the Carmacks Copper Project and the Redstone Project to Copper North and the Island Copper property. Advisors' Opinion:- [By Hebba Investments]
Therefore the situation is still very bullish for investors in physical gold and the gold ETFs (GLD, CEF, and PHYS). Investors interested in leveraging this situation into higher potential profits may also consider buying gold miners such as Randgold (GOLD), Goldcorp (GG), Yamana Gold (AUY), and any of the other gold miners. Finally, those willing to shoulder much larger risks may consider some of the exploration and micro-cap companies that offer significant profits at a high risk such as Chesapeake Gold (CHPGF.PK), Pretium Resources (PVG), Western Copper (WRN), or any other of the junior exploration companies. Though investors should keep in mind that gold mining companies and explorers do not always rise with a rising gold price - do your research before you invest in the miners.
Hot Up And Coming Companies For 2014: Teucrium Wheat Fund (WEAT)
Teucrium Wheat Fund (the Fund) is a commodity pool. The Fund is a series of the Teucrium Commodity Trust (Trust). The Fund provides investors unleveraged direct exposure to wheat without the need for a futures account. The investment objective of the Fund is to have the daily changes in percentage terms of a weighted average of the closing settlement prices for three futures contracts for wheat (Wheat Futures Contracts) that are traded on the Chicago Board of Trade (CBOT), which includes the second-to-expire CBOT Wheat Futures Contract, weighted 35%; the third-to-expire CBOT Wheat Futures Contract, weighted 30%, and the CBOT Wheat Futures Contract, weighted 35%. The Fund is managed by Teucrium Trading, LLC. Advisors' Opinion:- [By Paul Ausick]
The Teucrium Wheat Fund (NYSEMKT: WEAT) closed down 2.43% on Friday to finish the week at $16.47. For the week the fund was up 0.8%. The 52-week range is $13.31 to $19.50. Like corn, the price is up more than 12% since the beginning of the year and down 10.5% over the past 12 months. This fund trades averages just 41,000 shares traded in a day, but nearly tripled that on Friday, when wheat prices fell more than 2% on the CBOT to close at $6.955 a bushel.
Hot Up And Coming Companies For 2014: Autoliv Inc (ALV)
Autoliv, Inc. (Autoliv) is a holding company. Autoliv is the supplier of automotive safety systems, with a range of product offerings, including modules and components for passenger and driver-side airbags, side-impact airbag protection systems, seatbelts, steering wheels, safety electronics, whiplash protection systems and child seats, as well as night vision systems, radar and other active safety systems. Autoliv has two main operating segments: airbags/seatbelt (including restraint electronics) products and active safety electronics products. In March 2010, the Company acquired Visteon Corporation's radar system business. In April 2010, the Company acquired Delphi's Occupant Protection Systems (OPS) operations in Korea and China. In addition, in April 2010, Autoliv Inc.'s Automotive Holding AS increased its stake in Norma AS from 51% to 93.74%. Additionally, Skandinaviska Enskilda Banken AB and ING Luxembourg SA sold their 6.67% and 10% stake, respectively, held in Norma AS. In October 2010, the Company acquired 51% interest in Bejing Delpi Automotive Safety Products. In November 2011, the Company acquired the airbag cushion cut&sew assets from Milliken. In June 2012, the Company sold its subsidiary Autoliv Mekan AB to Verktygs Allians i Hassleholm AB.
Autoliv has approximately 80 wholly or partially owned or leased production facilities located in 28 countries, consisting of both component factories and assembly factories. The Company�� component factories manufacture inflators, initiators, textile cushions, webbing materials, electronics, pressed steel parts, springs and overmoulded steel parts used in seatbelt and airbag assembly, seat subsystems, steering wheels and its active safety and night vision systems, and its other safety electronic systems. During the year ended December 31, 2010, Autoliv�� revenues were approximately 67% of airbags and associated products and approximately 33% of seatbelts and associated products. The Company�� markets are in Europe, North A! merica, Asia-Pacific and Japan. Its customers include the car manufacturers.
During 2010, the products manufactured by Autoliv�� consolidated subsidiaries consisted of approximately 121 million complete seatbelt systems (of which approximately 49 million were fitted with pretensioners), approximately 57 million side-impact airbags (including curtain airbags), approximately 28 million frontal airbag modules, approximately 12 million steering wheels, approximately 11 million electronic units (airbag control), approximately 0.4 million active safety systems and 0.1 million night vision systems. Autoliv owns two principal subsidiaries, AAB and Autoliv ASP, Inc. (ASP). Its AAB and ASP are developers, manufacturers and suppliers to the automotive industry of automotive safety systems. AAB and ASP�� products include seatbelts, frontal and side-impact airbags, steering wheels and seat sub-systems, as well as components for such systems.
Advisors' Opinion:- [By Sarah Jones]
Allianz (ALV) gained 3.6 percent to 120.70 euros after reporting a 24 percent rise in first-quarter profit to about 1.7 billion euros after results improved at all of its businesses. Operating profit of 2.8 billion euros also topped analysts��estimates.
- [By Tom Stoukas]
Deutsche Lufthansa AG (LHA) and Allianz SE (ALV) led airlines and insurers lower, retreating at least 1.5 percent. Bayerische Motoren Werke AG (BMW) slid 1.6 percent. Deutsche Bank AG (DBK) rose after JPMorgan Chase & Co. boosted its recommendation on the shares. Gildemeister AG (GIL) added 3.4 percent after Deutsche Bank upgraded the maker of cutting tools.
No comments:
Post a Comment